直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Pharmaceutical

About

Pharmaceutical is part of our work in Life Sciences.

Breakthrough discoveries and innovations require strong protection

People rely on the pharmaceutical industry for life-saving drugs and treatments, as well as those that improve the quality of life. Even with billions of dollars invested in research and development, few drugs make it through clinical trials and stringent regulatory clearances necessary to get to market. For those that do, it is crucial that the companies have protected the intellectual property (IP) underlying new drugs and treatments. Finnegan has a long history of working with innovative pharmaceutical companies to protect and maximize their valuable IP rights and assets, strategizing prosecution pathways and portfolio planning.

Understanding the law, science, and technology

Our clients’ business and IP assets are global; protecting these assets across jurisdictions is increasingly challenging. With offices around the world and experience with multinational companies, Finnegan has the resources and experience to formulate and execute global strategies for pharmaceutical companies. The fast pace of new discoveries and their commercial applications require a comprehensive grasp of the IP legal issues and the industry insight to understand the scientific and strategic implications of the advancements.

With experience addressing virtually every type of IP issue for our pharmaceutical clients, we help by:

  • Representing clients in complex pharmaceutical patent infringement and trade secret cases, including Hatch-Waxman litigation
  • Litigating high value products in district and appellate courts with experienced trial and appellate teams
  • Developing and executing prosecution strategies to both protect a client’s products and analyze those of its competitors, thus helping ensure that the client realizes value from its IP assets
  • Preparing and negotiating licenses, assessing the licensing value of competitors’ patents, and guiding clients in decisions to license 
  • Providing due diligence for merger and acquisition and partnership targets 
  • Providing counsel on business-related matters, including antitrust and competition issues 
  • Determining priority in complex interferences 
  • Advising on potential litigation strategies, and asserting and defending patents in court
  • Providing trademark prosecution and counseling services 

We work with clients innovating and advancing science in myriad fields, including:

  • Antibody therapies—small and large molecules 
  • Atypical antipsychotic drugs
  • Sustained-release formulations 
  • Vaccines 

 

Everyone in this industry

Experience

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products*

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias*

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers*

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company*

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief*

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.

Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer*

Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer.

More

Insights

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

At the PTAB Blog

Squires Issues Precedential Decision Clarifying Obviousness-Type Double Patenting Rejections

August 17, 2026

Conference

13th Annual Summit for Women Leaders in Life Sciences Law

July 29-30, 2026

Boston

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Federal Circuit IP Blog

“2” Does Not Provide Written Description Support for “1”: Federal Circuit Affirms District Court’s Invalidation of Patent

July 8, 2026

Articles

Genus Claiming (Including Means Plus Function “MPF” Claiming) in Biotech and Pharma: Doctrinal Trajectory and Drafting Strategies

June 2026

More

Upcoming Events

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

News

Award/Ranking

Fourteen Finnegan Attorneys Named to the 2026 IAM Strategy 300 List

August 13, 2026

Award/Ranking

Partner Jeffrey M. Jacobstein Named Finalist for New England Legal Awards

August 10, 2026

Award/Ranking

Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards

July 15, 2026

Commentary

Finnegan Taps Partner from Kirkland to Boost IP Team

June 12, 2026

Media Mention

Finnegan Hires Kirkland & Ellis Litigator for London Office

June 8, 2026

Commentary

Finnegan Hires Kirkland Partner as It Eyes UK Growth

June 8, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP